These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35023177)

  • 41. Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.
    Santos Bravo M; Plault N; Sánchez Palomino S; Mosquera Gutierrez MM; Fernández Avilés F; Suarez Lledo M; Sabé Fernández N; Rovira M; Alain S; Marcos Maeso MÁ
    J Infect Dis; 2021 Sep; 224(6):1024-1028. PubMed ID: 33475730
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.
    Avery RK; Marty FM; Strasfeld L; Lee I; Arrieta A; Chou S; Tatarowicz W; Villano S
    Transpl Infect Dis; 2010 Dec; 12(6):489-96. PubMed ID: 20682012
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effective Letermovir Prophylaxis of CMV infection post allogeneic hematopoietic cell transplantation: Results from the French temporary authorization of use compassionate program.
    Beauvais D; Robin C; Thiebaut A; Alain S; Coiteux V; Ducastelle-Lepretre S; Marçais A; Ceballos P; Xhaard A; Redjoul R; Nguyen S; Brissot E; Joris M; Turlure P; Rubio MT; Chevallier P; Bénard N; Liautard C; Yakoub-Agha I
    J Clin Virol; 2022 Mar; 148():105106. PubMed ID: 35182958
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update.
    Sellar RS; Peggs KS
    Expert Opin Biol Ther; 2014 Aug; 14(8):1121-6. PubMed ID: 24762099
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Letermovir for the management of cytomegalovirus infection.
    Bowman LJ; Melaragno JI; Brennan DC
    Expert Opin Investig Drugs; 2017 Feb; 26(2):235-241. PubMed ID: 27998189
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
    Lin A; Flynn J; DeRespiris L; Figgins B; Griffin M; Lau C; Proli A; Devlin SM; Cho C; Tamari R; Jakubowski AA; Papadopoulos EB; Giralt SA; Perales MA; Seo SK; Shaffer B
    Transplant Cell Ther; 2021 Jan; 27(1):85.e1-85.e6. PubMed ID: 33053449
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Single-center experience with use of letermovir for treatment of CMV infection in stem cell transplant recipients.
    Kachur E; Roshdy D; Hamadeh I; Dodd B; Shahid Z
    Transpl Infect Dis; 2021 Apr; 23(2):e13502. PubMed ID: 33171005
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
    Jorgenson MR; Kleiboeker H; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
    Transpl Infect Dis; 2022 Feb; 24(1):e13766. PubMed ID: 34799964
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Letermovir treatment for CMV infection in kidney and pancreas transplantation: A valuable option for complicated cases.
    Ortiz F; Lempinen M; Aaltonen S; Koivuviita N; Helanterä I
    Clin Transplant; 2022 Feb; 36(2):e14537. PubMed ID: 34797574
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Maribavir: a novel antiviral agent with activity against cytomegalovirus.
    Trofe J; Pote L; Wade E; Blumberg E; Bloom RD
    Ann Pharmacother; 2008 Oct; 42(10):1447-57. PubMed ID: 18698013
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of letermovir as cytomegalovirus prophylaxis in adult recipients of allogeneic hematopoietic stem cell transplantation in Hong Kong.
    Chan TS; Cheng SS; Chen WT; Hsu DC; Chau RW; Kang SH; Alsumali A; Kwong YL
    J Med Econ; 2020 Dec; 23(12):1485-1492. PubMed ID: 33155494
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.
    Hecke SV; Calcoen B; Lagrou K; Maertens J
    Future Microbiol; 2019 Feb; 14():175-184. PubMed ID: 30644320
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
    Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
    Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.
    Marty FM; Ljungman P; Papanicolaou GA; Winston DJ; Chemaly RF; Strasfeld L; Young JA; Rodriguez T; Maertens J; Schmitt M; Einsele H; Ferrant A; Lipton JH; Villano SA; Chen H; Boeckh M;
    Lancet Infect Dis; 2011 Apr; 11(4):284-92. PubMed ID: 21414843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation.
    Deleenheer B; Spriet I; Maertens J
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1197-1207. PubMed ID: 30479172
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis.
    Chen K; Arbona-Haddad E; Cheng MP; McDonnell AM; Gooptu M; Orejas JL; Timblin K; Silverman E; Al-Hamed R; Soiffer RJ; Hammond SP; Marty FM
    Transpl Infect Dis; 2021 Aug; 23(4):e13619. PubMed ID: 33866648
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus.
    Chou S; Ercolani RJ; Derakhchan K
    Antiviral Res; 2018 Sep; 157():128-133. PubMed ID: 30040968
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients.
    Prohn M; Cho CR; Viberg A; Dykstra K; Davis C; Sabato P; Stone J; Badshah C; Murata Y; Leavitt R; Fancourt C; Macha S
    Clin Pharmacol Ther; 2022 Feb; 111(2):485-495. PubMed ID: 34674258
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis.
    Turner N; Strand A; Grewal DS; Cox G; Arif S; Baker AW; Maziarz EK; Saullo JH; Wolfe CR
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
    Jorgenson MR; Descourouez JL; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
    Transpl Infect Dis; 2021 Aug; 23(4):e13693. PubMed ID: 34309158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.